Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program

  • As previously announced, Valneva SE VALN said it would not invest in further COVID-19 vaccine development, VLA2001, without a new partnership. However, it is completing the remaining clinical studies and submissions.
  • Last week, the Committee for Medicinal Products for Human Use of the European Medicines Agency backed VLA2001 approval in adults as a booster dose after at least seven months following primary vaccination with VLA2001 (homologous booster dose) or with an adenoviral vector COVID-19 vaccine (heterologous booster dose).
  • Related: Valneva Touts Additional Positive Heterologous Booster Data From COVID-19 Vaccine Study.
  • In Phase 3 Study COV-Compare study, neutralizing antibodies six months after the second dose of the primary vaccination with VLA2001 was non-inferior compared to the active comparator AZD1222, better known as AstraZeneca Plc's AZN Covishield.
  • The fold decline of neutralizing antibodies over six months after a second vaccination with VLA2001 was similar to the active comparator and less pronounced than other licensed COVID-19 vaccines. 
  • Additionally, VLA2001-304 Phase 3 study in older adults showed that VLA2001 was well tolerated when administered as a two-dose or three-dose immunization.
  • In this age group, a two-dose vaccination with VLA2001 was inferior regarding geometric mean titers and seroconversion rates compared to younger adults. 
  • After two doses, immunogenicity in older adults was at a level that could correlate with 60-70% vaccine efficacy against original SARS-CoV-2. A third dose further increased immunogenicity with a vaccine efficacy of over 90%.
  • Price Action: VALN shares traded flat at $12.29 on the last check Thursday.
  • Photo Via Wikimedia Commons

Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine